3 results
The primary objective is to evaluate the safety and efficacy of the PulseCath during support of patients with impaired ventricular function, for a period between 24 hours minimum and 14 days maximum. Safety will be assessed by the incidence of…
The key objective is to personalize tacrolimus treatment for children with a renal transplant by using dosing algorithms to calculate both the individual*s tacrolimus starting dose and follow-up doses. Secondary aims are evaluating the role of the…
The purpose of this first-in-human study is to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses (MADs) of DYNE-101 administered intravenously (IV) to participants with DM1.…